Stanford Downgrades Cynosure (CYNO) to Hold
More News related to CYNO
- Romeo and Juliette Laser Hair Removal Is First Center in New York City to Own Cynosure's New Elite MPX(TM) Laser System
- Cynosure (CYNO) Posts Q3 Loss of $0.15
- Cynosure Reports Third Quarter 2009 Financial Results
- Trading Radar for 10/27: Visa (V), Baidu.com (BIDU), WYNN Resorts (WYNN), RF Micro (RFMD), BP (BP) Report
- Cynosure Enhances Industry-Leading Smartlipo Family with 1440 nm Wavelength
Stanford Group downgrades Cynosure (Nasdaq: CYNO) from Buy to Hold.
Shares of Cynosure are down another 6% today following a Q4 warning issued yesterday morning. The stock fell more than 11% yesterday on the news.
Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular lesions and pigmented lesions, temporarily reduce the appearance of cellulite, treat wrinkles, skin texture, skin discoloration and skin tightening, and to perform minimally invasive procedures for LaserBodySculpting for the removal of unwanted fat.
Related Categories
DowngradesStocks Mentioned
-0.34Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
